Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Partially HLA-matched unrelated donor cells refer to a cellular therapy product used in the microtransplantation (MST) protocol developed for patients with acute myeloid leukemia (AML) who are ineligible for standard allogeneic stem cell transplantation. This approach, specifically studied by the University of Sydney in the SCRAMBLE trial, involves the infusion of donor peripheral blood stem cells or marrow cells following consolidation chemotherapy. Unlike traditional transplantation, MST does not require post-infusion immunosuppression, aiming to induce a transient micro-chimerism that triggers a graft-versus-leukemia (GVL) effect to eradicate residual disease while minimizing the risk of graft-versus-host disease (GVHD).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Partially HLA-matched unrelated donor cells (University of Sydney).